Optimizing Gastroenterology Prior Authorization in Indiana

The Landscape of GI Prior Authorization in Indiana

Gastroenterology practices in Indiana operate within a healthcare ecosystem shaped by state-specific Medicaid managed care plans and the footprints of major commercial payers. While the core clinical criteria for GI services remain consistent with national guidelines, regional payer policies and administrative processes can introduce variability. Efficient management of these state-specific factors is crucial for minimizing delays and denials.

High-Volume Prior Authorization Categories in Gastroenterology

• **IBD Biologics:** TNF inhibitors (adalimumab, infliximab), integrin inhibitors (vedolizumab), IL-12/23 inhibitors (ustekinumab), JAK inhibitors (tofacitinib, upadacitinib), S1P modulators (ozanimod, etrasimod), and risankizumab for Crohn's disease.
• **Hepatitis C Direct-Acting Antivirals (DAAs):** Sofosbuvir-velpatasvir (Epclusa) and glecaprevir-pibrentasvir (Mavyret), with pathways differing for treatment-naive vs. treatment-experienced patients.
• **Advanced Imaging:** MRCP, MR enterography, and CT enterography for IBD assessment and other abdominal indications.
• **Endoscopic Procedures:** Capsule endoscopy (CPT 91110), small-bowel enteroscopy, ERCP, and EUS for specific diagnostic and therapeutic indications.
• **Specialty Drugs for Functional GI Disorders:** Eluxadoline, prucalopride, linaclotide, and plecanatide for conditions like IBS-D, chronic constipation, and IBS-C/CIC.

Key Documentation Requirements for GI Prior Authorizations

Payer policies for gastroenterology services heavily rely on guidelines from organizations such as ACG, AGA, and AASLD. Comprehensive documentation is paramount to demonstrate medical necessity and ensure approval. This often includes detailed clinical notes, diagnostic test results, and evidence of adherence to step therapy protocols.

Common Denial Reasons in Gastroenterology PA Workflows

• **Step Therapy Non-Compliance:** Failure to document trial and failure of conventional therapies (e.g., 5-ASA, immunomodulators) before biologics, or not attempting biosimilars first.
• **Missing Disease Severity Documentation:** Absence of critical scores like Mayo score for UC or CDAI/Harvey-Bradshaw for Crohn's.
• **Incomplete Screening Documentation:** Lack of pre-biologic TB or hepatitis screening results.
• **Fibrosis Stage Gaps for Hep C DAAs:** Insufficient documentation of fibrosis stage via FibroSure, transient elastography, or biopsy.
• **Inappropriate-Use Criteria for Imaging:** Lack of clear clinical correlation for advanced imaging requests like MR enterography.
• **Insufficient Prior Workup for Capsule Endoscopy:** Failure to document prior upper GI series or EGD before requesting capsule endoscopy.

Addressing Workflow Complexities in Indiana GI Practices

Gastroenterology practices face several unique workflow constraints that impact prior authorization efficiency. The chronic nature of conditions like IBD necessitates periodic re-authorization for biologics, requiring continuous documentation of disease response. Additionally, the variability in biosimilar substitution policies across payers and the distinction between medical and pharmacy benefit for the same biologic agent add layers of complexity. Klivira's platform is engineered to manage these nuances, providing streamlined processing for GI-specific PA challenges.

Klivira's Strategic Approach to GI Prior Authorization Automation

Klivira integrates directly with EMRs and payer portals, providing an intelligent automation solution for gastroenterology prior authorizations. Our platform incorporates ACG/AGA-guideline-aware step therapy logic for IBD biologics, automates treatment-status classification from EMR medication history, and supports comprehensive Hep C DAA workflows including genotype and fibrosis stage documentation. We also manage periodic re-authorization cycles for chronic treatments and facilitate medical-vs-pharmacy benefit routing for biologic agents.